More: American Thoracic Society (ATS) 2008 International Conference

ATS 2008: Perspectives on Methicillin-resistant Staphylococcus aureus: The Persistent Pathogen CME

May 16 - 21, 2008, Toronto, Ontario, Canada

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the American Thoracic Society. Conference news does not receive grant support and is produced independently.

Release Date: June 18, 2008; Valid for credit through June 18, 2009

Credits Available
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Thoracic Society. These materials and the related activity are not sanctioned by the American Thoracic Society or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Medscape
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Evaluate recent data on the effectiveness of preventative measures on MRSA infections in the ICU
  2. Compare new therapy options for MRSA with existing therapies based on reported efficacy
  3. Describe the impact of inappropriate therapy for MRSA on hospital length of stay
Authors and Disclosures

Andrew Shorr, MD, MPH
Disclosure: Andrew Shorr, MD, MPH, has disclosed that he has received grants for educational activities and has served as an advisor or consultant to Pfizer, Johnson & Johnson, Boehringer Ingelheim, GlaxoSmithKline, sanofi, and Merck. Dr. Shorr has also disclosed that he has received grants for clinical research from Pfizer, Johnson & Johnson, Boehringer Ingelheim, GlaxoSmithKline, and sanofi.


Jennifer Brown, PhD
Disclosure: Jennifer Brown, PhD, has nothing to disclose.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.